Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435481 | 0.78 | CYP19A1 (0.41) | IDO1ALDH1A1KDM4EKMT2A | |
| SCHEMBL2432794 | 0.76 | MAPT (0.39) | IDO1ALDH1A1ALOX15MAPTKDM4E | |
| SCHEMBL2434369 | 0.75 | HTR1A (0.40) | IDO1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL2432485 | 0.74 | HTR1A (0.39) | IDO1ALDH1A1NPSR1MAPTKDM4E | |
| SCHEMBL2432159 | 0.73 | NPC1 (0.37) | IDO1ALDH1A1LMNASIRT5MAPT | |
| SCHEMBL2430714 | 0.73 | PRKDC (0.42) | ALDH1A1LMNAALOX15GAASMN1; SMN2 | |
| SCHEMBL2430093 | 0.72 | IDO1 (0.40) | IDO1ALDH1A1LMNASIRT5MAPT | |
| SCHEMBL2430483 | 0.72 | IDO1 (0.38) | IDO1ALDH1A1LMNASIRT5MAPT | |
| SCHEMBL2429922 | 0.71 | DCTPP1 (0.37) | IDO1ALDH1A1SIRT5MAPTKDM4E | |
| SCHEMBL2430469 | 0.70 | IDO1 (0.36) | IDO1ALDH1A1LMNASIRT5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | IDO1 274/4885ALDH1A1 568/4885LMNA 4163/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | IDO1 274/4885ALDH1A1 568/4885LMNA 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.